THX Pharma and Biocodex Strike €173m Rare-Disease Licensing Pact
A new strategic licensing agreement between THX Pharma and Biocodex is aiming to push forward two experimental programmes across three rare, inherited diseases where patients and families often face life-changing symptoms with limited treatment options.
The partnership, announced this month, hands Biocodex the rights to develop and commercialise two drug candidates across defined territories, while keeping THX Pharma in the driver’s seat for clinical development.
A deal designed to move fast where options are few
The agreement is valued at up to €173 million, made up of a €12 million upfront payment, additional development and commercial milestone payments, and tiered double-digit royalties on net sales should the medicines reach the market.
Behind the headline number is a familiar reality in rare disease R&D: progress is expensive, timelines are long, and success often depends on whether a smaller innovator can secure the resources and global infrastructure needed to run late-stage trials and prepare for market access.
This deal is structured to do exactly that – pairing THX’s assets with Biocodex’s development and commercial capabilities.
What Biocodex is licensing and where
The agreement covers two candidates – one with global rights, the other with regional rights:
Batten-1: Biocodex receives a global exclusive licence to develop and commercialise Batten-1 for juvenile Batten disease (CLN3), a rare neurological condition that often affects children and progresses over time.
TX01: Biocodex receives a regional exclusive licence for TX01 in the United States and Canada for the treatment of Gaucher disease and Niemann-Pick disease type C – genetically inherited conditions associated with severe and progressive visceral, haematological, and/or neurological impairments.
In other words, Biocodex is taking on a worldwide role for Batten-1, while focusing TX01 specifically on North America – two very different commercial footprints, shaped by development strategy and where each programme may have the clearest path to patients.
Who does what: clinical leadership vs commercial execution
One of the most notable parts of the collaboration is the division of responsibilities.
THX Pharma will lead the clinical development of both programmes, supported financially and scientifically by Biocodex. That gives THX continuity and control over the scientific direction – often important when programmes are based on deep specialist expertise and existing clinical plans.
Biocodex, meanwhile, will oversee compassionate use (compassionate access), along with market access and commercial activities in the licensed territories.
Compassionate use is particularly significant in rare diseases, where clinicians and families may seek pre-approval access under regulated frameworks when there are few or no alternatives.
Why the companies say this matters
Both organisations describe the programmes as meaningful scientific and medical advances – language that reflects not just ambition, but the stark unmet need that defines many ultra-rare neurological and metabolic disorders.
THX Pharma’s President and CEO framed the agreement as a major step forward and a value-creation milestone, emphasising that partnering with a leading French pharmaceutical company validates the scientific and strategic value of THX’s assets.
They highlighted Biocodex’s clinical development capabilities, industrial and regulatory expertise, and international commercial presence in rare neurological diseases – strengths that, in THX’s view, enable a more ambitious approach across Europe and North America, ultimately improving the odds of success for patients.
Biocodex’s CEO, for their part, positioned the partnership as tightly aligned with the company’s innovation strategy focused on rare diseases with high unmet medical need, adding that THX’s scientific expertise and values were central to Biocodex’s decision.
The statement also noted an intention to continue working with organisations including the Beyond Batten Disease Foundation – a reminder that in rare disease development, patient communities and advocacy groups often play a critical role in awareness, recruitment, and long-term support.
The broader signal to the rare-disease world
This agreement lands at a moment when rare-disease pipelines are increasingly shaped by partnerships: specialist biotechs generate early innovation, then collaborate with companies that can scale clinical operations and handle market access – particularly in regions where reimbursement pathways and specialist-centre networks are complex.
By giving Biocodex exclusive rights (globally for Batten-1, and in the United States and Canada for TX01), THX Pharma is effectively trading geographic commercial control for the funding, infrastructure, and regulatory horsepower needed to push these programmes forward.
Biocodex, in turn, is doubling down on an area – rare neurological disease – where it believes it can build durable expertise and deliver real-world impact.
Conclusion
In sum, THX Pharma and Biocodex have put pen to paper on a strategically structured licensing partnership that targets three rare, inherited diseases with serious progressive consequences and limited therapeutic options.
Valued at up to €173 million with an upfront €12 million, milestones, and double-digit royalties, the deal gives Biocodex global rights to Batten-1 and North American rights to TX01, while THX Pharma continues to lead clinical development with Biocodex providing support and taking responsibility for compassionate use, market access, and commercial execution in licensed territories.
If the collaboration delivers on its promise, it won’t just mark a financial milestone for the companies – it could represent a meaningful step toward new options for families who have been waiting far too long.
News Credits: Thx Pharma and Biocodex sign rare disease licensing deal
Things you may also like:
- AutoTom: £3m Government-Backed Push to Rebuild Britain’s Tomato Industry
- FDA Grants Breakthrough Status to En Carta’s Single-Use Lyme Test
- Twinings Adds a Peach Twist to Its Sparkling Tea Push